The current state of understanding of oncology expanded access programs in Malaysia.
| Autor: | Yong FL; Medical Affairs, Pfizer, Malaysia., Tan WC; Medical Affairs, Pfizer, Malaysia. wuanchin.tan@pfizer.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Medical journal of Malaysia [Med J Malaysia] 2024 Mar; Vol. 79 (2), pp. 191-195. |
| Abstrakt: | Introduction: An expanded access program (EAP) is a regulatory mechanism that provides access to an investigational drug, which is not approved for use, in treating life-threatening conditions when all the standard-ofcare treatments are exhausted. Materials and Methods: An online, anonymous, voluntary survey was conducted to assess the level of knowledge and understanding about EAPs among Malaysian oncologists using SurveyMonkey® between April 2020 and June 2020. Oncologists who had enquired about EAP in the past, were invited at random to participate in the survey. Participants who did not provide consent or failed to complete the survey were excluded. Results: A total of 15 oncologists participated in the survey, from both public (46.6%) and private (46.6%) practices. Most respondents (80%) had filed between 1 to 10 EAP applications in the past 12 months. For 73.3% respondents, resources or training were not provided for EAPs from institutions. Around 53% of the respondents reported that their knowledge of EAPs and application processes including country regulations is 'good'. The majority of respondents (73.3%) reported that the educational modules on an overview of EAPs, country regulations and the EAP application process will be beneficial. Most participants received information about the existing EAPs either by reaching out to a pharmaceutical sponsor or through another health care provider and some received information about the existing EAPs through their institutions or patients/caregivers. Most of the respondents recommended that pharmaceutical companies should have readily available information related to the availability and application of EAPs for all pipeline products on their websites. Discussion: EAPs are crucial treatment access pathways to provide investigational drugs to patients who have exhausted their treatment options and are not eligible for participation in clinical trials. Malaysian oncologists have a fair understanding about the EAPs and the application processes. Conclusion: Additional training and awareness are needed for Malaysian oncologists to upscale the utilisation of EAPs. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|